Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants




Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants

BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) — Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the pricing of an underwritten public offering of 7,175,000 shares of its common stock at a public offering price of $16.00 per share and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 2,200,000 shares of common stock at a public offering price of $15.9999 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each pre-funded warrant. The gross proceeds to Bicara from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Bicara, are expected to be approximately $150 million, excluding any exercise of the underwriters’ option to purchase additional shares and excluding the exercise of any pre-funded warrants. All shares and pre-funded warrants in the offering are being sold by Bicara. The offering is expected to close on or about February 26, 2026, subject to the satisfaction of customary closing conditions. In addition, Bicara has granted the underwriters a 30-day option to purchase up to 1,406,250 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions.

Bicara intends to use the net proceeds of the offering to further invest in and build its medical and commercial infrastructure to support a planned regulatory filing and commercial launch for ficerafusp alfa, if approved, in the U.S.; to further accelerate the development of ficerafusp alfa in 1L R/M HPV-negative HNSCC, including a less frequent dosing schedule; to fund manufacturing costs for ficerafusp alfa for ongoing and anticipated drug development efforts; to fund early signal-finding to support future indication expansion for ficerafusp alfa; and for other general corporate purposes.

Morgan Stanley, TD Cowen, BofA Securities, Cantor and Stifel are acting as joint book-running managers for the offering.

The securities described above will be offered by Bicara pursuant to an effective “shelf” registration statement on Form S-3 (File No. 333-290707) that was filed with the Securities and Exchange Commission (the “SEC”) on October 3, 2025 and declared effective on November 26, 2025. The securities may be offered only by means of a prospectus supplement and an accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the proposed offering will be filed with the SEC. Electronic copies of the preliminary prospectus supplement and, when available, copies of the final prospectus supplement, and the accompanying prospectus relating to the offering may be obtained by visiting the SEC’s website at www.sec.gov or by contacting Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2^nd Floor, New York, NY 10014, or by email at prospectus@morganstanley.com; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at TDManualrequest@broadridge.com; BofA Securities, NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email at dg.prospectus_requests@bofa.com; Cantor Fitzgerald & Co., Attention: Equity Capital Markets, 110 E. 59^th Street, 6th Floor, New York, NY 10022, or by email at prospectus@cantor.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Bicara Therapeutics
Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara’s lead program, ficerafusp alfa, is a first-in-class bifunctional antibody designed to drive tumor penetration by breaking barriers in the tumor microenvironment that have challenged the treatment of multiple solid tumor cancers. Specifically, ficerafusp alfa combines two clinically validated targets: an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (“TGF-β”). Through this targeted mechanism, ficerafusp alfa reverses the fibrotic and immune-excluded tumor microenvironment driven by TGF-β signaling to enable tumor penetration that drives deep and durable responses. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types.

Forward-Looking Statements
Litigation Reform Act of 1995, as amended. These statements may be identified by words such as “may,” “might,” “will,” “could,” “would,” “should,” “plan,” “anticipate,” “intend,” “believe,” “expect,” “estimate,” “seek,” “predict,” “future,” “project,” “potential,” “continue,” “target” and similar words or expressions, or the negative thereof, are intended to identify forward-looking statements, although not all contain identifying words. Any statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, the completion of the underwritten public offering, the potential exercise by the underwriters of the option to purchase additional shares, the anticipated proceeds and use of such proceeds from the offering, and timing of the closing of the offering. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks and uncertainties that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to uncertainties inherent in the development of product candidates, including the conduct of research activities and the conduct of clinical trials; uncertainties as to the availability and timing of results and data from clinical trials; whether results from prior preclinical studies, preliminary or interim data from earlier stage clinical trials will be predictive of the results of subsequent preclinical studies and clinical trials; regulatory developments in the United States and foreign countries; whether Bicara’s cash resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in Bicara’s filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2024, its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 and any subsequent filings Bicara makes with the SEC. In addition, any forward-looking statements represent Bicara’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Bicara explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Contacts:

Investors
Jenna Cohen
IR@bicara.com

Media
Amanda Lazaro
1AB
Amanda@1abmedia.com

Ivim Health GLP-1 Weight Loss Program: Individualized Dosing, Pricing, and What Consumers Should Know in 2026




Ivim Health GLP-1 Weight Loss Program: Individualized Dosing, Pricing, and What Consumers Should Know in 2026

An informational overview of Ivím Health’s compounded semaglutide and tirzepatide telehealth program, including GLP-1 ID cost breakdown, weekly provider check-in structure, clinical claims analysis, and safety considerations for prospective patients

Columbus, OH, Feb. 24, 2026 (GLOBE NEWSWIRE) — Disclaimer: This article is for informational purposes only. It is not medical advice. Always consult a qualified healthcare professional before starting any medication or weight loss program. If you purchase through links in this article, a commission may be earned at no additional cost to you. 

Updated program disclosures for Ivím Health’s GLP-1 ID Individualized Dosing program have recently become publicly available. The telehealth weight loss service offers compounded semaglutide and tirzepatide with weekly provider check-ins and personalized dose adjustments. The program, which launched in early 2026, uses weekly check-ins and individualized titration based on patient-reported progress and tolerance.

According to publicly available disclosures on the company’s website, the program combines virtual consultations with licensed healthcare providers, compounded GLP-1 medications, and ongoing dose modifications tailored to individual patient responses. The service is available nationwide through Ivím Health’s telehealth platform, with pricing as shown on the company’s website starting at $75 per month for compounded semaglutide and $149 per month for compounded tirzepatide, plus a $74.99 monthly program fee.

Key Takeaways: What You Need to Know About Ivim Health’s GLP-1 Weight Loss Platform

• Compounded Medications: The program uses compounded formulations of semaglutide and tirzepatide, which are not FDA-approved and have not undergone FDA review for safety, effectiveness, or manufacturing quality. The FDA has warned that some compounded products may contain salt forms such as semaglutide sodium or semaglutide acetate, which are different active ingredients than those in FDA-approved medications.
• Weekly Provider Monitoring: Patients complete weekly check-ins through the Ivím Health app, with licensed providers reviewing progress and adjusting doses accordingly
• Pricing Structure: According to the company’s website, compounded semaglutide starts at $75/month, compounded tirzepatide at $149/month, with a mandatory $74.99/month program fee for all participants
• Program Commitment: Programs are structured based on duration selected at checkout (1, 2, 4, or 6 months), according to the company’s website
• Clinical Claims: According to publicly available disclosures on the company’s website, Ivím Health states that its patients lost an average of 46% more weight over 68 weeks compared to another published clinical GLP-1 trial, though this was not a head-to-head comparison study

For those evaluating whether this telehealth platform meets their needs, view the current GLP-1 ID offer (official Ivím Health page) to review the full eligibility requirements and service details.

In This Release

• Understanding Compounded GLP-1 Medications vs. FDA-Approved Brands
• How Ivim Health’s GLP-1 Weight Loss Individualized Dosing Model Works
• Clinical Results and Weight Loss Claims Analysis
• Published Program Pricing and Fee Structure
• Provider Credentials and Telehealth Legitimacy
• Program Commitment Details
• Safety Considerations and Side Effects
• Frequently Asked Questions
• Contact Information

Understanding Compounded GLP-1 Medications vs. FDA-Approved Brands

The Ivím Health GLP-1 ID program centers on compounded formulations of semaglutide and tirzepatide, which differ significantly from FDA-approved brand-name medications like Wegovy and Zepbound. According to publicly available disclosures on the company’s website, these compounded medications have not undergone FDA review for safety, effectiveness, or manufacturing quality.

Compounded medications are custom-prepared by specialized pharmacies based on a healthcare provider’s prescription. They are not subject to the same rigorous clinical trial requirements and manufacturing oversight as FDA-approved drugs. The FDA has issued guidance on compounded GLP-1 medications, noting that while compounding can serve legitimate medical needs, patients should understand these products do not carry the same regulatory assurances as approved medications.

Critical FDA Warning on Salt Forms: The FDA has warned that some compounded products marketed as “semaglutide” may contain salt forms such as semaglutide sodium or semaglutide acetate, which are different active ingredients than the base semaglutide in FDA-approved medications. Patients should verify the specific formulation with their provider before starting treatment.

According to publicly available disclosures on the company’s platform, patients who prefer branded medications “still have full access to Zepbound and Wegovy if you choose through our traditional GLP-1 program.” However, the GLP-1 ID Individualized Dosing program specifically utilizes compounded formulations as its primary offering.

The distinction matters for several reasons:

• Regulatory Status: FDA-approved medications have completed Phase 1, 2, and 3 clinical trials demonstrating safety and efficacy in thousands of patients. Compounded medications do not require this level of evidence.
• Quality Control: FDA-approved drugs are manufactured under Current Good Manufacturing Practice (cGMP) standards with batch testing and quality assurance. Compounded medications are prepared by individual pharmacies with varying quality control processes.
• Dosing Precision: Brand-name GLP-1 medications come in pre-filled pens with precise, standardized doses. Compounded medications may have variability in concentration and require more careful dose measurement.
• Insurance Coverage: FDA-approved medications may be covered by insurance (though coverage for weight loss is limited). Compounded medications are typically not covered by insurance plans.

The company positions compounded formulations as part of its individualized dosing care structure, alongside weekly check-ins and ongoing adjustments based on reported tolerance and progress.

How the Ivim Health GLP-1 Weight Loss Individualized Dosing Model Works

The program’s core differentiator, according to Ivím Health, is its weekly provider check-in and dose adjustment protocol. Standard telehealth GLP-1 programs typically follow manufacturer-recommended titration schedules with monthly or less frequent provider contact. Ivím’s care structure involves weekly patient-reported data collection and provider review.

According to publicly available disclosures on the company’s website, the program flow follows this general structure:

Eligibility and Intake

Patients complete what the company calls a “dynamic health questionnaire” that covers medical history, current medications, weight loss goals, and potential contraindications for GLP-1 therapy. Specific medical eligibility criteria are not detailed on the company’s public website.

Provider Consultation

A licensed provider conducts a video or chat-based consultation to review the patient’s health history, discuss treatment goals, and create an initial treatment plan. The company states that it works with licensed healthcare providers, though it does not publish detailed credential information for individual practitioners on its public website. Patients should verify their assigned provider’s credentials and licensure status in their state before beginning treatment.

Program Selection

Patients select a program duration (1, 2, 4, or 6 months) and pay the program fee. The company recommends most patients begin with the “Jumpstart” option, described as a 4-month commitment. The provider then finalizes the care plan and sends prescriptions to the compounding pharmacy.

Weekly Check-Ins

Patients complete weekly check-ins through the Ivím Health mobile app, reporting symptoms, side effects, weight changes, and subjective experience. According to publicly available disclosures on the company’s website, providers review this data and make “doctor-approved changes based on your feedback,” adjusting doses to minimize side effects while maintaining weight loss progress.

Refills and Ongoing Support

Medication refills are timed to the selected program duration. The company states that “refills are timed to your plan, ensuring consistent care and continuous support every step of the way.”

The program also includes what the company describes as additional support services. For individuals considering whether this level of monitoring aligns with their weight loss goals, view the current GLP-1 ID offer (official Ivím Health page) to understand what’s included in the monthly cost.

Clinical Results and Weight Loss Claims Analysis

The company’s website references clinical data comparing its protocol to published research. These claims are worth examining closely, particularly the methodology and limitations the company itself has disclosed.

Primary Claim: 46% More Weight Loss

According to publicly available disclosures on the company’s website, Ivím Health states that “Ivim patients following the Ivim Protocol lost an average of 46% more weight over 68 weeks when compared to another published clinical GLP-1 trial that included a daily 500-calorie deficit, 150 minutes of weekly exercise, and in-person counseling every four weeks.”

The company explicitly states this was “not a head-to-head study,” meaning Ivím patients were not directly randomized against a control group in the same trial. Instead, the company appears to be comparing its patient outcomes to results from a separate, previously published study. This type of indirect comparison has significant limitations:

• Different Patient Populations: The compared studies may have enrolled patients with different baseline characteristics, comorbidities, or weight loss history
• Different Time Periods: Studies conducted at different times may reflect different clinical practices, patient expectations, or medication formulations
• Different Outcome Measures: How weight loss was measured, when it was measured, and how dropouts were handled may differ between studies
• Selection Bias: Patients who complete a 68-week telehealth program may differ systematically from those who complete an in-person clinical trial

The company references the comparison trial as including “a daily 500-calorie deficit, 150 minutes of weekly exercise, and in-person counseling every four weeks.” These are substantial lifestyle interventions that may not be replicated in all real-world telehealth settings, making the comparison complex to interpret.

The lack of a head-to-head comparison means the 46% figure should be interpreted as a retrospective analysis rather than evidence from a controlled trial. Prospective patients evaluating this claim should consider requesting additional methodological details from the company directly.

Specific Weight Loss Percentages

The company’s website also states:

• “27% weight loss with tirzepatide”
• “22% weight loss with semaglutide”

These figures are presented as average outcomes but come with an important footnote: “These results include data from patients using both FDA-approved and compounded formulations.” This means the reported outcomes combine patients using brand-name Zepbound/Wegovy with those using compounded medications, making it impossible to determine the specific efficacy of the compounded formulations offered through the GLP-1 ID program.

The company also includes a disclaimer stating “Based on our internal data and individual patient outcomes may vary. This does not constitute a guarantee of specific results.”

Weight Loss Calculator

The Ivím Health website includes an interactive weight loss calculator that generates estimated weight loss based on a user’s current weight. This calculator appears to be based on the average percentage weight loss figures cited by the company, but individual results will vary significantly based on adherence, baseline metabolism, comorbidities, and other factors.

Publication Status

The company references clinical data on its website and includes a footer reference to “Individualized virtual integrative medicine (IVIM): A clinical model for enhanced GLP-1 therapeutic outcomes.” Prospective patients may wish to request the full study citation and publication details directly from the company to evaluate the methodology and peer review status independently.

Published Program Pricing and Fee Structure

The Ivím Health GLP-1 ID program involves multiple line items, all of which are presented on the company’s website.

Medication Costs (as shown on the company’s website):

• Compounded Semaglutide: Starting at $75/month
• Compounded Tirzepatide: Starting at $149/month

The company uses the phrase “starting at,” suggesting these prices may increase at higher doses. GLP-1 medications are typically titrated upward over several months, meaning patients may pay more than the starting price as their dose increases. The website does not provide a complete dose-based pricing table.

Program Fee:

• $74.99/month (mandatory for all participants)

This fee is separate from medication costs and covers weekly provider check-ins, app access, virtual consultations, and other program services. It applies regardless of which medication a patient selects.

Because GLP-1 medications are typically titrated upward over time, total program costs may vary depending on dose adjustments and program duration selected. The company offers 1, 2, 4, and 6-month program options. Prospective patients should review current pricing details directly with the provider before enrolling.

Payment and Refund Policy

According to the company’s terms, cancellation may be limited after fulfillment begins. The company’s terms describe fees and potential refunds in certain circumstances, with specific amounts varying by program duration. Patients should review the complete terms and conditions and clarify the payment schedule and cancellation policies directly with Ivím Health before enrolling.

Provider Credentials and Telehealth Legitimacy

Ivím Health operates as a telehealth platform connecting patients with licensed healthcare providers for GLP-1 weight loss treatment. For anyone considering the service, it’s worth looking at the provider network and the regulatory framework that governs it.

Provider Network

The company’s website states that Ivím Health works with licensed healthcare providers who are authorized to prescribe GLP-1 medications in the patient’s state. The platform references 92 providers. However, the company does not publish detailed credential information for individual practitioners on its public website. Patients should verify their assigned provider’s credentials and licensure status in their state before beginning treatment.

The weekly check-in care structure means patients have more frequent provider contact than typical telehealth weight loss programs, which may involve only monthly consultations or automated refill systems. However, the depth and format of these weekly interactions (app-based questionnaire review vs. direct provider communication) may vary.

Telehealth Regulatory Framework

Telehealth prescribing of prescription medications is regulated at both federal and state levels. The Ryan Haight Act and subsequent DEA guidance establish requirements for prescribing controlled substances via telemedicine. GLP-1 medications (semaglutide and tirzepatide) are not controlled substances, but state medical boards regulate telemedicine practice within their jurisdictions.

Patients should verify that:

• Their assigned provider is licensed in their state of residence
• The provider has conducted an appropriate medical evaluation before prescribing
• The compounding pharmacy is licensed and operates under state pharmacy board oversight
• The telehealth platform complies with HIPAA privacy requirements

Compounding Pharmacy Standards

The company states that medications are prepared by compounding pharmacies operating under state pharmacy regulators and applicable compounding standards. Patients may wish to request specific information about which pharmacy will prepare their medication and verify that pharmacy’s licensure and inspection history through their state pharmacy board.

Program Commitment Details

The Ivím Health GLP-1 ID program requires patients to select a program duration at the time of enrollment. These commitment terms are worth reviewing carefully before signing up.

Available Program Durations

The company’s website lists the following options:

• 1-month program
• 2-month program
• 4-month program (“Jumpstart” — company recommended)
• 6-month program

The company recommends most patients begin with the 4-month “Jumpstart” option, though the clinical rationale for this specific duration is not detailed on the public website.

Dose Adjustments During the Program

The individualized dosing care structure means medication doses may change during the program based on weekly check-ins. If a patient’s dose is increased, medication costs may increase beyond the “starting at” prices listed on the website. The company does not provide a complete dose-escalation pricing table on its public website.

Refills and Continuation

The company states that “refills are timed to your plan, ensuring consistent care and continuous support every step of the way.” Its terms specify that medications are dispensed in no more than two-month (8-week) increments, with continued shipment conditional on completing a required clinical follow-up around the eighth week. Patients who wish to continue treatment beyond their initial program duration would need to enroll in a new program cycle.

Safety Considerations and Side Effects

GLP-1 receptor agonists like semaglutide and tirzepatide are associated with a well-documented side effect profile. Anyone considering these medications should be familiar with the potential risks.

This section is a general overview and is not a complete list of risks, contraindications, or interactions. Patients should review individualized safety considerations with their prescribing clinician.

Common Side Effects

The most frequently reported side effects of GLP-1 medications include:

• Nausea (most common, especially during dose escalation)
• Vomiting
• Diarrhea
• Constipation
• Abdominal pain
• Decreased appetite
• Fatigue
• Headache

These side effects are typically most pronounced during the initial weeks of treatment and when doses are increased. The Ivím Health weekly check-in care structure is designed, according to the company, to allow dose adjustments that minimize side effects while maintaining weight loss progress.

Serious Risks and Contraindications

GLP-1 medications carry boxed warnings and contraindications that patients must discuss with their healthcare provider:

• Thyroid C-Cell Tumors: Semaglutide and tirzepatide carry a boxed warning about thyroid C-cell tumors observed in rodent studies. Patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should not use these medications.
• Pancreatitis: Acute pancreatitis has been reported in patients taking GLP-1 medications. Patients with a history of pancreatitis should discuss this risk with their provider.
• Gallbladder Disease: Rapid weight loss can increase the risk of gallstones. GLP-1 medications have been associated with cholelithiasis and cholecystitis.
• Kidney Problems: Dehydration from vomiting and diarrhea can worsen kidney function, particularly in patients with pre-existing kidney disease.
• Diabetic Retinopathy: In patients with type 2 diabetes, rapid improvement in blood sugar control has been associated with worsening of diabetic retinopathy.
• Hypoglycemia: When used with insulin or insulin secretagogues, GLP-1 medications can increase the risk of low blood sugar.

Drug Interactions

GLP-1 medications slow gastric emptying, which can affect the absorption of oral medications. Patients taking the following should discuss timing and monitoring with their healthcare provider:

• Oral contraceptives
• Antibiotics requiring specific blood levels
• Medications with a narrow therapeutic index
• Insulin or other diabetes medications

Pregnancy and Breastfeeding

GLP-1 medications may not be appropriate during pregnancy or breastfeeding. Patients should discuss reproductive health considerations, including contraception timing before and after treatment, with their prescribing clinician.

Compounded Medication Considerations

Because the Ivím Health GLP-1 ID program uses compounded formulations that have not undergone FDA review, patients should be aware that:

• The safety profile may differ from FDA-approved formulations
• Quality control processes vary by compounding pharmacy
• Concentration accuracy may have more variability than pre-filled pens
• Long-term safety data specific to compounded formulations is limited

Patients should report any side effects to their healthcare provider through the weekly check-in system and seek immediate medical attention for severe symptoms such as persistent severe abdominal pain, signs of pancreatitis, or allergic reactions.

Frequently Asked Questions

Is Ivím Health a licensed telehealth platform?

Ivím Health operates as a telehealth coordination platform connecting patients with licensed healthcare providers for GLP-1 weight loss treatment. According to the company, prescriptions may be issued following a clinical evaluation by a licensed provider, with fulfillment through a pharmacy partner. However, the compounded medications used in the GLP-1 ID program have not undergone FDA review for safety, effectiveness, or manufacturing quality. Patients should verify their provider’s credentials and the compounding pharmacy’s licensure before beginning treatment.

What’s the difference between compounded and FDA-approved GLP-1 medications?

FDA-approved medications like Wegovy and Zepbound have completed extensive clinical trials demonstrating safety and efficacy, are manufactured under strict quality control standards, and come in pre-filled pens with precise dosing. Compounded medications are custom-prepared by pharmacies, have not undergone FDA clinical trial review, and may have more variability in concentration and quality control. The FDA has warned that some compounded products may contain salt forms (semaglutide sodium or semaglutide acetate) that are different active ingredients than those in FDA-approved medications.

How does the weekly check-in system work?

The company describes a process where patients complete weekly check-ins through the Ivím Health mobile app, reporting symptoms, side effects, weight changes, and how they’re feeling overall. Licensed providers then review this data and make dose adjustments aimed at minimizing side effects while maintaining weight loss progress.

What happens if I experience severe side effects?

Patients experiencing severe side effects should report them immediately through the app and seek medical attention if symptoms are serious. The weekly monitoring system is designed to allow dose adjustments in response to side effects, but patients should not wait for their next scheduled check-in if symptoms are severe or concerning.

Is the program covered by insurance?

Compounded medications are typically not covered by insurance plans. The Ivím Health website does not indicate insurance acceptance for the GLP-1 ID program. Patients should verify coverage options directly with the company and their insurance provider.

What is the cancellation policy?

According to publicly available disclosures on the company’s website, cancellation may be limited after fulfillment begins. Because GLP-1 medications are prescribed and shipped based on the selected program length, the commitment begins at enrollment. The company’s terms describe fees and potential refunds in certain circumstances. Patients should review the complete terms and conditions before purchasing.

How do I know which program duration to choose?

The company recommends most patients begin with the 4-month “Jumpstart” program. GLP-1 medications typically require several months of treatment to achieve significant weight loss, as doses are gradually increased to therapeutic levels. Patients should discuss their weight loss goals and timeline with their provider during the initial consultation.

Can I use Ivím Health if I have diabetes?

The company’s website does not specify whether the GLP-1 ID program is available for patients with type 2 diabetes or is restricted to weight loss in non-diabetic patients. Patients with diabetes should discuss their condition during the intake questionnaire and initial consultation to determine eligibility.

What if I need a higher dose than the “starting at” price?

The company’s website indicates medication costs “start at” $75/month for semaglutide and $149/month for tirzepatide, suggesting prices may increase at higher doses. A complete dose-based pricing table is not provided on the public website. Patients should request clarification on dose-escalation costs before enrolling in the program.

Contact Information

For more information about the Ivím Health GLP-1 ID Individualized Dosing program, including current pricing, eligibility requirements, and provider credentials, view the current GLP-1 ID offer (official Ivím Health page).

Ivím Health can also be reached directly by email at help@ivimhealth.com or by phone at (877) 581-1741.

Patients with specific medical questions should consult their healthcare provider before starting any weight loss program or medication. Those interested in FDA-approved GLP-1 medications should discuss brand-name options with their provider as an alternative to compounded formulations.

About This Publication

This article was published for informational and educational purposes only. The content is based on publicly available information from the company’s website and general medical knowledge about GLP-1 medications. This publication maintains editorial independence and does not provide medical advice, diagnosis, or treatment recommendations. Individual results with any weight loss program or medication will vary. Always consult a qualified healthcare professional before starting any new treatment.

Affiliate Disclosure: If you purchase services through links in this article, a commission may be earned at no additional cost to you. View the current GLP-1 ID offer (official Ivím Health page) to confirm current program terms.

Medical Disclaimer: This content is for informational purposes only and is not a substitute for professional medical advice. Always consult a qualified healthcare professional before making changes to your treatment plan. Compounded medications are not FDA-approved and have not undergone FDA review for safety, effectiveness, or manufacturing quality.

Program and Pricing Disclaimer: Program availability, patient experiences, and pricing may vary. Always confirm the latest details directly with the official provider before making a purchase decision.

Publisher Responsibility Disclaimer: The publisher of this article has made every effort to ensure accuracy at the time of publication. We do not accept responsibility for errors, omissions, or outcomes resulting from the use of the information provided. Readers are encouraged to verify all details directly with the official source before making a purchase decision.

CONTACT: Email: help@ivimhealth.com 
Phone: (877) 581-1741 

Pulmo Balance: Ingredients, Pricing, and What Consumers Should Know in 2026




Pulmo Balance: Ingredients, Pricing, and What Consumers Should Know in 2026

An informational overview examining category context, publicly available product disclosures, and what consumers often consider when researching respiratory support supplement options

New York, NY, Feb. 24, 2026 (GLOBE NEWSWIRE) — DISCLAIMER: This press release is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. The statements made about Pulmo Balance have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary. Consult your healthcare provider before starting any new dietary supplement, especially if you have existing health concerns or take medications. This article may contain affiliate links, meaning a commission may be earned at no additional cost to you if you purchase through the links provided. Pricing and availability are subject to change — visit the official website for current pricing.

This release is an informational overview of publicly available disclosures for Pulmo Balance and broader consumer research behavior within the respiratory support supplement options category. Nothing in this content should be interpreted as medical advice, a product endorsement, or a performance claim.

As respiratory support supplement options remain an active area of consumer research in 2026, Pulmo Balance product disclosures are available through the company’s website, including ingredient listings and published policy information. With more people researching what’s out there, detailed product information is accessible for anyone trying to better understand their supplement options.

This article provides informational context about the respiratory wellness category and summarizes what Pulmo Balance Research has disclosed about its product. Readers seeking primary-source detail can View the current Pulmo Balance offer (official Pulmo Balance page) to review the company’s complete product disclosures directly. This article does not assess product effectiveness or outcomes and focuses solely on publicly available disclosures.

Why Consumers Are Researching Respiratory Support Supplement Options

Respiratory wellness supplements are a category that continues to draw consumer attention as more people look into natural options that complement their existing health routines. Whether it’s seasonal changes, environmental factors, or a general interest in day-to-day respiratory comfort, people are paying closer attention to what products are available and what factors might be worth considering before making a purchase.

For many people, this research starts with a straightforward question — what’s actually in these products, and how transparent is the company behind them? That’s a reasonable instinct, and it’s exactly the kind of thinking that may help consumers compare disclosures more effectively. The respiratory support supplement category includes a wide range of products with different ingredient profiles, pricing structures, and company disclosures, which can make comparison shopping feel overwhelming without organized information.

Ingredient transparency, manufacturing practices, and refund policies are among the factors consumers commonly research alongside ingredient lists — a pattern that reflects broader awareness around supplement label literacy in general.

What Respiratory Support Supplements Typically Refer To

The term “respiratory support supplement” generally refers to dietary supplement products that contain ingredients traditionally associated with lung and airway wellness. These are not medications. They are not FDA-approved treatments for any disease or condition. They fall under the Dietary Supplement Health and Education Act (DSHEA), which means companies can market them with structure/function claims but cannot claim to diagnose, treat, cure, or prevent any specific disease.

Products in this category commonly feature botanical extracts, enzymes, antioxidant compounds, and mushroom-derived ingredients. Some brands provide detailed Supplement Facts panels with individual ingredient amounts, while others group ingredients into proprietary blends. Understanding what category a product falls into — and what regulatory framework governs it — is an important first step for anyone doing their homework before purchasing.

What Botanical Extracts and Enzyme Compounds Are

Botanical extracts are concentrated preparations derived from plants — leaves, bark, roots, or flowers — that have histories of traditional use in various herbal wellness practices. Common botanical extracts found in the respiratory support category include mullein leaf, pine bark, and stinging nettle. These ingredients are widely available individually and are also commonly included in combination formulas. The presence of a botanical ingredient in a supplement does not constitute a claim about what that ingredient does.

Enzyme compounds, such as bromelain (derived from pineapple), are proteins that facilitate biological processes. Enzymes appear in many supplement categories and are sometimes included alongside botanical ingredients. As with botanicals, the inclusion of an enzyme in a supplement formula does not constitute an efficacy claim for the finished product.

How Consumers Evaluate Respiratory Support Supplements

If you’re comparing respiratory support supplements — and the fact that you’re reading this suggests you might be — there are a few non-performance factors worth looking at before you focus on any single product. These won’t tell you whether a product “works,” but they will tell you a lot about the company behind it.

Ingredient disclosure completeness is one of the first things to check. Does the company list every ingredient with its individual amount, or does the label use a proprietary blend that groups ingredients together without showing how much of each one you’re actually getting? Full disclosure gives you the ability to cross-reference with independent research if you choose to.

Dosage transparency matters because research on individual ingredients is typically conducted at specific dosage levels. If a company doesn’t disclose how much of each ingredient is in the formula, there’s no way for a consumer to compare what’s in the bottle to what’s been studied independently.

Refund and return policy clarity is another indicator worth examining. Some companies advertise generous return windows but include specific procedural requirements. Reading the full refund policy — not just the marketing headline — before purchasing is a smart move.

Manufacturing and sourcing disclosures vary significantly across brands. Some companies identify where products are manufactured, whether facilities are FDA-registered, and what quality control measures are in place. Others provide minimal detail.

None of these factors tell you whether a supplement will meet your expectations. But they give you a clearer picture of how a company operates — and that’s useful information regardless of which product you’re evaluating.

Ingredient Transparency in the Respiratory Support Supplement Category

Ingredient transparency is a factor many consumers consider when researching supplements. Companies vary in how much detail they provide about formulation, sourcing, and manufacturing processes. Some brands publish complete Supplement Facts panels with individual ingredient amounts, while others use proprietary blends that group ingredients together.

According to publicly available company disclosures, Pulmo Balance lists Mullein Extract, Bromelain Powder, Maritime Pine Bark, Stinging Nettle Extract, Tiger Milk Mushroom, Quercetin Dihydrate Extract, and BioPerine as its primary ingredients. The company’s published materials describe these as a blend selected for their traditional and research-associated roles in respiratory wellness contexts. Readers interested in specific dosage information can review the company’s product page and any available labeling disclosures for the most current formulation details, as individual ingredient amounts are not disclosed in publicly available marketing materials. This overview is informational only and does not evaluate product outcomes or make performance claims.

Important context about ingredient research: Some independent research exists related to individual ingredients listed in the Pulmo Balance formula. Studies cited by the company examine individual botanical ingredients in respiratory-related research contexts. However, these studies evaluate individual ingredients at specific dosages — they do not assess the Pulmo Balance formulation itself. Because the specific dosages in the Pulmo Balance formula are not publicly disclosed, direct comparisons to research dosages are not possible. Research on individual ingredients does not automatically translate to efficacy claims for a proprietary blend. The company explicitly states it is not endorsed by, sponsored by, or affiliated with any of the organizations that published the referenced research.

Understanding Supplement Labels in the Respiratory Category

If you’re new to researching supplements, a quick primer on how to read labels can save you a lot of confusion. The Supplement Facts panel is the most important section on any product — it’s where you’ll find serving size, servings per container, and (ideally) individual ingredient amounts.

Products that list ingredients inside a “proprietary blend” are required to show the total combined weight of all ingredients in the blend, but they are not required to disclose how much of each individual ingredient is included. This is legal under current FDA labeling rules, but it does limit your ability to evaluate what you’re actually taking on a per-ingredient basis.

For respiratory support products specifically, you may also want to look at whether the label includes common allergen disclosures, whether the product is described as non-GMO or third-party tested, and whether the company provides customer service contact information directly on the product page. These are transparency signals — not guarantees of quality — but they help you build a more complete picture before making a decision.

What Pulmo Balance Research Discloses About Its Product

Pulmo Balance is a dietary supplement manufactured by Pulmo Balance Research, a United States-based company, according to the company’s website. The product is marketed as a natural lung support formula containing seven ingredients and is positioned for adults seeking to incorporate respiratory wellness support into their daily routines.

The company’s published materials reference a blend of ingredients commonly listed within the respiratory support category. According to the company’s website, Paul Whitmore is identified as the creator of Pulmo Balance. The company describes the formula as designed for respiratory wellness support and recommends consistent use as part of a broader wellness routine.

The company describes the product as non-GMO, non-habit forming, and assembled in the United States. The recommended usage is two capsules daily with a meal, according to the company’s website. The product is not recommended for individuals under 18 or for pregnant or nursing mothers.

The company recommends a usage period of four months or longer, describing this as its suggested timeline for incorporating the supplement into a daily wellness regimen. As with any dietary supplement, individual experiences vary, and the company notes this in its publicly available materials.

Important context: Pulmo Balance is a dietary supplement, not a medication. It has not undergone FDA evaluation and is not intended to diagnose, treat, cure, or prevent any disease. Anyone with existing health concerns or who takes medications should consult a healthcare provider before starting any new supplement.

Readers who want to review the company’s full ingredient list, product disclosures, and current availability can View the current Pulmo Balance offer (official Pulmo Balance page) to access complete product information directly from the company.

Pulmo Balance Pricing Structure and Purchase Options

Pulmo Balance is offered in multiple package configurations through the company’s direct-to-consumer website. According to the company, multi-bottle packages may include bundled digital materials — described as “The 7-Day Lung Reset Protocol” and “The Inflammation-Free Breathing Blueprint” (digital downloads, not physical books) — along with shipping incentives on certain package tiers.

The company offers single-bottle, three-bottle, and six-bottle configurations. Specific pricing, availability, and promotional details may change over time and can be reviewed on the official product page.

According to the company, orders are shipped within 24 working hours using premium carriers, and customers receive tracking numbers via email. Domestic orders typically arrive within 5 to 10 days, according to the company’s website.

Refund Policies and Customer Support Disclosures

According to the company’s published policies, Pulmo Balance Research describes a 90-day refund policy and provides customer service contact methods on its website. The company’s published return policy includes specific requirements for obtaining a refund, including return authorization procedures and product return conditions. Readers should review the full terms directly on the official page before making a purchase decision.

Who May Want to Consult a Healthcare Professional

While respiratory support supplements are widely available, certain individuals may want to discuss supplementation with a qualified healthcare professional before use. This commonly includes people with existing respiratory conditions or chronic health concerns, anyone currently taking prescription medications or managing ongoing health conditions, women who are pregnant or nursing, individuals with known allergies to any listed ingredient, and anyone under the age of 18.

Many people choose to consult qualified healthcare professionals for personalized guidance on whether any supplement fits their individual health circumstances. This is particularly relevant for anyone with existing health conditions or those taking medications. A healthcare provider can evaluate whether a supplement is appropriate alongside your current health plan — and that conversation is always worth having.

Frequently Asked Questions About Pulmo Balance

What is Pulmo Balance?
According to the company’s website, Pulmo Balance is a dietary supplement containing seven primary ingredients. It is manufactured by Pulmo Balance Research, a United States-based company, and is marketed as a natural respiratory support formula for adults.

How is Pulmo Balance taken?
According to the company, the recommended usage is two capsules daily with a meal. The company recommends consistent use for four months or longer as part of a wellness routine.

Are individual ingredient amounts disclosed?
Specific dosages of each ingredient in the Pulmo Balance formula are not disclosed in publicly available company materials. Readers can review the company’s product page and any available labeling disclosures for the most current formulation details.

Where is Pulmo Balance manufactured?
According to the company’s website, Pulmo Balance is assembled in the United States.

What is the refund policy?
According to the company, Pulmo Balance purchases are covered by a 90-day return policy with specific terms and conditions. Readers should review the complete refund policy on the company’s website before ordering.

Can Pulmo Balance be taken with medications?
Anyone currently taking prescription medications or managing ongoing health conditions should consult their healthcare provider before starting Pulmo Balance or any new dietary supplement.

Where to Review Complete Product Information

According to the company’s website, Pulmo Balance is available exclusively through its direct-to-consumer platform. To review current pricing, package options, the full ingredient list, available labeling disclosures, and the company’s complete terms and conditions, View the current Pulmo Balance offer (official Pulmo Balance page).

For customer service inquiries, the company provides contact information on the official website, including email support at support@pulmobalance.com and phone support at +1-888-834-4386 (Mon–Sun, 10 AM–1 AM EST).

About This Publication

This press release is published for informational and educational purposes only. It is not medical advice and does not constitute an endorsement or recommendation of any product. Readers should conduct their own research and consult qualified healthcare professionals before making health-related decisions. This publication may contain affiliate links, meaning a commission may be earned at no additional cost to you if you purchase through the links provided.

Final Disclaimer: The statements made about Pulmo Balance have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary. Pricing and availability are subject to change. Always verify current product information, pricing, and terms directly with the manufacturer before making a purchase decision.

CONTACT: support@pulmobalance.com 
+1-888-834-4386 (Mon–Sun, 10 AM–1 AM EST)

Junshi Biosciences Announces Strategic Collaboration with Antengene to Evaluate Combination Therapy with JS207 (PD-1/VEGF BsAb) and ATG-037 (Oral CD73 Inhibitor)




Junshi Biosciences Announces Strategic Collaboration with Antengene to Evaluate Combination Therapy with JS207 (PD-1/VEGF BsAb) and ATG-037 (Oral CD73 Inhibitor)

SHANGHAI, Feb. 24, 2026 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the company has entered into the strategic collaboration with Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK). Under the collaboration, the parties will jointly evaluate the synergistic therapeutic potential of Junshi Biosciences’ JS207, a recombinant humanized anti-PD-1/VEGF bispecific antibody, in combination with Antengene’s ATG-037, an oral small-molecule CD73 inhibitor, in patients with solid tumors in Chinese Mainland, with the goal of identifying clinical signals across multiple tumor types.

JS207, Junshi Biosciences’ independently developed recombinant humanized anti-PD-1/VEGF bispecific antibody, has demonstrated promising anti-tumor activity and a manageable safety profile in both preclinical and clinical studies. JS207’s preclinical studies demonstrated its robust anti-tumor efficacy in multiple tumor models and supported a differentiated mechanism of action, with VEGFA shown to enhance JS207’s antigen binding activity, T-cell activation potency and internalization of cell-surface PD-1.

In a poster presented at ESMO Asia 2025, JS207 monotherapy showed encouraging efficacy across solid tumors. 62 patients with PD-L1 positive non-small cell lung cancer (NSCLC) received JS207 monotherapy as first-line treatment, and achieved an objective response rate (ORR) of 58.1% and a disease control rate (DCR) of 87.1%. Clinical activity has also been observed in additional tumor types, including hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC), supporting the potential of PD-1/VEGF dual targeting across multiple tumor settings.

To date, JS207 has 11 ongoing phase 2 clinical studies, exploring its use in combination with chemotherapy, monoclonal antibodies (mAb), antibody-drug conjugates (ADCs) and other drugs in NSCLC, colorectal cancer, triple-negative breast cancer, liver cancer and other tumor types, with nearly 500 patients enrolled. Based on the accumulated data from these studies, the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application, allowing Junshi Biosciences to initiate an open-label, two-arm, randomized, active-controlled, Phase 2/3 clinical study comparing JS207 to nivolumab for the neoadjuvant treatment of patients with stage 2/3, resectable, actionable genomic aberration (AGA)-negative NSCLC.

ATG-037, Antengene’s orally administered small-molecule CD73 inhibitor, offers significant advantages over anti-CD73 mAbs. In preclinical studies, ATG-037 demonstrated stronger inhibition of cell-surface CD73 enzymatic activity and overcame the “hook effect” commonly observed with antibody-based approaches. In addition, ATG-037’s higher tissue penetration compared with antibodies may facilitate complete CD73 inhibition at the cellular level.

ATG-037 has demonstrated encouraging clinical activity in combination with anti-PD-1 therapy in patients with checkpoint inhibitor-resistant melanoma and NSCLC, based on the latest data presented at Antengene’s R&D Day in November 2025. In the ongoing Phase 1/1b STAMINA-01 study, the combination achieved an ORR of 33.3% with a DCR of 100% in patients with CPI-resistant melanoma, and an ORR of 21.4% with a DCR of 71.4% in patients with CPI-resistant NSCLC. The dataset was generated in Australia in patients with CPI-refractory solid tumors, with pembrolizumab and/or nivolumab as the predominant prior anti-PD-1 therapies, and more than 70% of melanoma patients were refractory to both anti-PD-1 mAb and anti-CTLA-4 mAb (ipilimumab). These results support ATG-037’s clinically meaningful activity across multiple tumor types, particularly in patients with prior immunotherapy resistance. Importantly, ATG-037 has demonstrated a favorable safety and tolerability profile in combination treatment, with no new or unexpected safety signals observed, including in patients receiving long-term therapy. Grade 3 or higher treatment-related adverse events only occurred in 7.9% of patients. Responses have also shown encouraging durability, including a patient who achieved a complete response and has remained on study for over three years and is currently receiving ATG-037 monotherapy for more than a year, as well as multiple patients with durations of response exceeding 12 months. These data support ATG-037’s potential role as a backbone agent for next-generation immuno-oncology combination regimens.

The scientific rationale for the collaboration is based on the complementary and potentially synergistic mechanisms of CD73 inhibition and dual PD-1/VEGF targeting. CD73 is recognized as a key regulator of immune suppression and angiogenesis within the tumor microenvironment through the generation of adenosine, which can dampen anti-tumor immune responses. In both clinical and preclinical settings, CD73 inhibitors have demonstrated meaningful synergy with anti-PD-1 mAbs. In addition, CD73 activity has been shown to promote angiogenesis, including through upregulation of VEGF signaling, and may contribute to the development of resistance to anti-VEGF therapies. Given the broad relevance of immune suppression, angiogenesis and adenosine signaling across solid tumors, this combination strategy has the potential to be applicable across multiple tumor types. Taken together, these observations suggest that combining CD73 blockade with PD-1/VEGF-directed approaches has the potential to enhance and sustain therapeutic effects. Together, the combination of ATG-037 with JS207 represents a potential “triple-axis” approach that simultaneously modulates immune checkpoint signaling, angiogenesis, and the adenosine pathway. With the potential to deepen responses while maintaining a favorable safety profile, the combination of ATG-037 with JS207 may further improve the durability of benefit and may translate into improved overall survival.

We look forward to the close collaboration between Junshi Biosciences and Antengene, leveraging their respective expertise in target biology and clinical development to accelerate the evaluation of JS207 in combination with ATG-037 across multiple solid tumor types, with the goal of identifying clinical signals and delivering more innovative treatment options for patients in Chinese Mainland.

About JS207

JS207, a recombinant humanized anti-PD-1/VEGF bispecific antibody, was independently developed by Junshi Biosciences for the treatment of advanced malignant tumors. To date, JS207 has been approved for conducting phase 2/3 clinical study, and it has 11 ongoing phase 2 clinical studies, exploring its use in combination with chemotherapy, mAbs, ADCs and other drugs in NSCLC, colorectal cancer, triple-negative breast cancer, liver cancer and other tumor types. Preclinical results of JS207 have been published in Frontiers in Immunology, while early-stage clinical data were first presented in a poster session at ESMO ASIA 2025.

JS207 can simultaneously bind to PD-1 and VEGFA with high affinity, effectively blocking the binding of PD-1 to PD-L1 and PD-L2 while also inhibiting the binding of VEGF to its receptor. JS207 has the efficacy of both immunotherapeutic drugs and anti-angiogenic drugs. Through the neutralization of VEGF, JS207 inhibits the proliferation of vascular endothelial cells, improves the tumor microenvironment, and increases the infiltration of cytotoxic T lymphocytes in the tumor microenvironment, thereby achieving better anti-neoplasm activity.

JS207’s design is based on the high-affinity, clinically proven and differentiated anti-PD-1 drug, toripalimab as the backbone. The anti-PD-1 moiety of JS207 adopts a Fab structure to maintain binding affinity to PD-1, thereby attaining better enrichment in the tumor microenvironment. The anti-VEGF moiety has a binding affinity for human vascular endothelial growth factor that is comparable to that of bevacizumab. In non-clinical in vitro cytological tests, compared with the combination of an anti-PD-1/PD-L1 monoclonal antibody and a VEGF monoclonal antibody, a bispecific antibody simultaneously targeting PD-1/PD-L1 and VEGF demonstrated significantly enhanced PD-1 antigen binding and internalization, as well as synergistic enhancement of the NFAT signaling pathway, thereby better activating immune cells in the tumor microenvironment.

About Junshi Biosciences

Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Five of the company’s products have received approvals in China and international markets, one of which is toripalimab, China’s first domestically produced and independently developed anti-PD-1 monoclonal antibody. Toripalimab has been approved in over 40 countries and regions including China, the US, and Europe. During the COVID-19 pandemic, Junshi Biosciences actively shouldered the social responsibilities of a Chinese pharmaceutical company through its involvement in developing etesevimab, MINDEWEI®, and other novel therapies for the prevention and treatment of COVID-19.

With a mission of “providing patients with world-class, trustworthy, affordable, and innovative drugs,” Junshi Biosciences is “In China, For Global.” At present, the company boasts approximately 2,500 employees in the United States (Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc.). For more information, please visit: http://www.junshipharma.com.

Junshi Biosciences Contact Information

IR Team:
Junshi Biosciences
info@junshipharma.com
+ 86 021-6105 8800

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800

Cannabix Technologies Closes Non-Brokered Private Placement




Cannabix Technologies Closes Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR
FOR DISSEMINATION IN THE UNITED STATES

VANCOUVER, British Columbia, Feb. 24, 2026 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (CSE: BLO) (the “Company” or “Cannabix”) announces it has closed its previously announced non-brokered private placement financing (the “Offering”) with the issuance of 1,400,000 units of the Company (the “Units”) at an issue price of CDN$0.50 per Unit for aggregate gross proceeds of CDN$700,000. Each Unit consists of one common share in the capital of the Company (a “Share”) and one non-transferable common share purchase warrant (a “Warrant”). Each Warrant is exercisable into one Share at an exercise price of CDN$0.65 per Share for a period of 24 months from the date of issuance, subject to the following acceleration right. If, at any time after the date of issuance of the Warrants, the closing price of the Shares on the Canadian Securities Exchange (or such other stock exchange on which the Shares may be traded from time to time) is at or above CDN$0.75 per Share for a period of 10 consecutive trading days (the “Triggering Event”), the Company may, within 5 days of the Triggering Event, accelerate the expiry date of the Warrants by giving notice thereof to the holders of the Warrants, by way of news release, and in such case the Warrants will expire on the first day that is 30 calendar days after the date on which such notice is given by the Company announcing the Triggering Event.

The net proceeds from the Offering are intended to be used to fund manufacturing inventory and labour, general and administrative expenses (including investor relations) and unallocated working capital.

In accordance with National Instrument 45-106 – Prospectus Exemptions (“NI 45-106”), the Units issued under the Offering were offered for sale to purchasers resident in Canada, except Quebec, the United States or countries other than the United States and Canada in reliance on the listed issuer financing exemption under Part 5A of NI 45-106 (the “Listed Issuer Financing Exemption”). Because the Offering was completed pursuant to the Listed Issuer Financing Exemption, the Units issued to subscribers in the Offering are not subject to resale restrictions in accordance with applicable Canadian securities legislation.

There is an offering document dated February 6, 2026, related to the Offering that can be accessed under the Company’s profile on SEDAR+ at www.sedarplus.ca and on the Company’s website. This offering document contains additional details regarding the Offering.

The CEO of the Company acquired an aggregate of 126,000 Units in the Offering, which participation constituted a “related party transaction” as defined under Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions (“MI 61-101”). Such participation is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as neither the fair market value of the Units acquired by the insider, nor the consideration for the Units paid by such insider, exceed 25% of the Company’s market capitalization. As required by MI 61-101, the Company advises that it expects to file a material change report relating to the Offering less than 21 days before completion of the Offering, which is necessary to complete the Offering in an expeditious manner and is reasonable in the circumstances.

The Company paid an aggregate of CDN$7,360 in cash as finder’s fees and issued 14,720 finder’s warrants, each entitling the holder to acquire one Share at a price of CDN$0.65 for a period of 24 months from the date of issuance, subject to the Acceleration Clause.

An investor of the Company holds a contractual participation right until May 15, 2026 in respect of equity financings by the Company. The Company received an executed waiver from such investor indicating that they will not exercise their participation right in connection with the Offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended (the “1933 Act”) or under any U.S. state securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act, as amended, and applicable state securities laws.

We seek Safe Harbor.

On behalf of the Board of Directors

“Rav Mlait”

CEO
Cannabix Technologies Inc.

For further information, contact the Company at info@cannabixtechnologies.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking, Cautionary Statements

This press release contains forward looking statements within the meaning of applicable securities laws. The use of any of the words “anticipate”, “plan”, “continue”, “expect”, “estimate”, “objective”, “may”, “will”, “project”, “should”, “predict”, “potential” and similar expressions are intended to identify forward looking statements. This press release contains forward looking statements concerning, without limitation, statements relating to the Offering (including with respect to the closing of the Offering, clearing any regulatory comments with respect to the Offering, and the Company’s intended use of proceeds from the Offering). Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company cannot give any assurance that they will prove correct. Since forward looking statements address future events and conditions, they involve inherent assumptions, risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of assumptions, factors and risks. These assumptions and risks include, but are not limited to, assumptions and risks associated with research, development and commercialization risks of its products; regulatory risks governing standards and use of our products; product liability; and future financing risks.

Management has provided the above summary of risks and assumptions related to forward looking statements in this press release in order to provide readers with a more comprehensive perspective on the Company’s future operations. The Company’s actual results, performance or achievement could differ materially from those expressed in, or implied by, these forward-looking statements and, accordingly, no assurance can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what benefits the Company will derive from them. These forward-looking statements are made as of the date of this press release, and, other than as required by applicable securities laws, the Company disclaims any intent or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or otherwise.

Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives




Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives

WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (Nasdaq: HOWL) (the “Company” or “Werewolf”), an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that the Company will explore a full range of strategic alternatives to advance its promising platform and drug development pipeline to maximize stockholder value. The Company has engaged Piper Sandler & Co. (“Piper Sandler”) to serve as exclusive financial advisor to assist in the strategic evaluation process.

“We have initiated a process to explore a range of alternatives available to the Company to maximize stockholder value. Such measures may include, among other options, a sale of the Company, a business combination or merger, a sale of assets, licensing or collaboration arrangements, or other strategic transactions,” said Dan Hicklin, Ph.D., President and CEO of Werewolf. “In addition to our clinical-stage candidates and our named earlier-stage candidates, our INDUKINE and INDUCER platforms provide exciting opportunities to apply our differentiated masking and protease linker technology in multiple additional modalities.”

The Company does not have a defined timeline for the exploration and evaluation of strategic alternatives and cannot confirm that the process will result in any strategic alternative being announced or consummated. The Company cannot provide any commitment regarding when or if this strategic evaluation process will result in any type of transaction, and there can be no assurance that such activities will result in any agreements or transactions that will enhance stockholder value. The Company does not intend to discuss or disclose further developments during this process unless and until its board of directors has approved a specific action or the Company has otherwise determined that further disclosure is appropriate.

About Werewolf Therapeutics
Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. The Company is leveraging its proprietary PREDATOR platform to design conditionally activated INDUKINE and INDUCER molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Werewolf’s INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. Werewolf has applied the same masking and linker technology that it uses in its INDUKINE molecules to advance the development of INDUCER molecules. Werewolf’s first INDUCER development candidate, WTX-1011, targets STEAP1 for prostate cancer, and its second INDUCER candidate, WTX-2022, targets CDH6 for ovarian and kidney cancer.

To learn more visit www.werewolftx.com or follow us on LinkedIn.

Cautionary Note Regarding Forward-Looking Statements:
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Werewolf’s strategy, future operations, prospects, plans, and objectives of management, including potential strategic partnerships; the potential activity and efficacy of product candidates in preclinical studies and clinical trials; and the anticipated safety profile of product candidates constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “aim,” “anticipate,” “believe,” “contemplate,” “continue,” “could,” “design,” “designed to,” “engineered,” “estimate,” “expect,” “goal,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “potential,” “predict,” “project,” “promise,” “should,” “target,” “will,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the development of product candidates, including the conduct of research activities, and the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials; whether preliminary or interim data from a clinical trial will be predictive of the future results of the trial and future clinical trials; the Company’s ability to manage cash resources and obtain additional cash resources to fund the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in the “Risk Factors” section of the Company’s most recent Form 10-Q filed with the Securities and Exchange Commission (SEC), and in subsequent filings the Company has made and may make with the SEC. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date of this press release. The Company anticipates that subsequent events and developments will cause its views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.

WEREWOLF^®, the WEREWOLF logo, PREDATOR^®, INDUKINE™, INDUCER™, and other Werewolf trademarks, service marks, graphics and logos are trade names, trademarks or registered trademarks of Werewolf Therapeutics, Inc., in the United States or other countries. All rights reserved.

Company Contact:
Steven Bloom
Chief Business Officer
Werewolf Therapeutics
sbloom@werewolftx.com

Piper Sandler Contacts:
Peter Day
Managing Director,
Piper Sandler & Co.
peter.day@psc.com

Michael Burton-Williams
Executive Director,
Piper Sandler & Co.
michael.burton-williams@psc.com

Investor Contact:
Dan Ferry
LifeSci Advisors
617.430.7576
daniel@lifesciadvisors.com

Media Contact:
Amanda Sellers
Deerfield Group
301.332.5574
amanda.sellers@deerfieldgroup.com

Spyre Therapeutics to Participate in Upcoming March Investor Conferences




Spyre Therapeutics to Participate in Upcoming March Investor Conferences

WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) — Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced that management will participate in the following upcoming investor conferences:

Event: TD Cowen 46th Annual Health Care Conference – Boston
Date: Tuesday, March 3, 2026
Presentation and Fireside Time: 3:10 pm ET

Event: Leerink Global Healthcare Conference – Miami
Date: Monday, March 9, 2026
Fireside Time: 8:40 am ET

Event: Jefferies Biotech on the Beach Summit – Miami
Date: Tuesday, March 10, 2026

Members of the Spyre management team will host one-on-one investor meetings during the conferences.

Live audio webcasts and replays of these events will be available on the Spyre investor events website at https://ir.spyre.com/events-and-presentations.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases. Spyre’s pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.

For more information, visit Spyre’s website at www.spyre.com.

For Investors:     
Eric McIntyre, Spyre Therapeutics
SVP of Finance and Investor Relations
Eric.mcintyre@spyre.com

Aktis Oncology to Present at Upcoming March Investor Conferences




Aktis Oncology to Present at Upcoming March Investor Conferences

BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) — Aktis Oncology, Inc. (NASDAQ:AKTS), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies, today announced that Matthew Roden, Ph.D., President and Chief Executive Officer of Aktis Oncology, will present at the following investor conferences in March 2026.

TD Cowen 46^th Annual Health Care Conference
Date & Time: Tuesday, March 3, 2026, at 1:10 p.m. ET
Location: Boston, MA

Leerink Partners Global Healthcare Conference
Date & Time: Monday, March 9, 2026, at 1:40 p.m. ET
Location: Miami, FL

A live webcast of the presentations may be accessed via the Investors section of the Aktis website at investors.aktisoncology.com. An archived replay of the event will be available on the website for approximately 90 days following the conference.

About Aktis’ Radioconjugate Platform
Aktis has developed a proprietary, isotope-agnostic miniprotein radioconjugate platform to selectively deliver the tumor-killing properties of radioisotopes to targeted tumors. Aktis’ therapeutic miniprotein radioconjugates are designed to maximize anti-cancer activity through high penetration, internalization and retention in cancer cells, while quickly clearing from normal organs and tissues. The Aktis platform further enables clinicians to visualize and verify target engagement with imaging isotopes prior to exposure to therapeutic radioisotopes. Leveraging this platform, Aktis is advancing a pipeline of next-generation targeted radiopharmaceuticals to address the unmet needs of patients across a broad spectrum of solid tumors.

About Aktis Oncology
Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. Aktis’ most-advanced program, AKY-1189, is a miniprotein radioconjugate targeting Nectin-4, with multi-indication potential across multiple tumor types, including locally advanced or metastatic urothelial cancer, breast cancer, non-small cell lung cancer, colorectal cancer, cervical cancer, and head and neck cancer. Aktis’ second pipeline program, AKY-2519, is a miniprotein radioconjugate targeting B7-H3 expressing tumors, including prostate, lung and other solid tumors. Aktis has a strategic collaboration with Eli Lilly and Company to leverage its miniprotein platform to develop novel radioconjugates outside of Aktis’ proprietary pipeline.

Media Contact:
Melone Communications, LLC
Liz Melone
617-256-6622
liz@melonecomm.com

Investor Contact:
Precision AQ
Alex Lobo
212-698-8802
alex.lobo@precisionaq.com

UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference




UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference

PRINCETON, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) — UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that management will present at the TD Cowen 46th Annual Health Care Conference to take place March 2-4, 2026.

TD Cowen 46th Annual Health Care Conference

The webcast from the conference will also be available on UroGen’s corporate website, under Events & Presentations. A replay will be available for approximately 30 days.

About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first product is approved to treat low-grade upper tract urothelial cancer, and UroGen’s second product is the first and only FDA-approved medication for adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Both medicines are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.UroGen.com to learn more or follow us on X (Twitter), @UroGenPharma. 

INVESTORS:

Vincent Perrone
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588 ext. 1093

MEDIA:

Cindy Romano
Director, Corporate Communications
cindy.romano@urogen.com
609-460-3566 ext. 1083

Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease




Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease

– Blinded evaluation of safety and tolerability data by the Safety Monitoring Committee from Cohort 1 and advancement to Cohort 2 is expected in 3Q 2026 –

– Advancement reflects continued execution of capital-efficient development strategy leveraging POZ Platform^™ –

HUNTSVILLE, AL, Feb. 24, 2026 (GLOBE NEWSWIRE) — Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company advancing drug candidates enabled by its proprietary POZ Platform^™ drug optimization technology, today announced that it has dosed the first patient in its Phase 1b registrational clinical trial evaluating SER-252 in patients with advanced Parkinson’s disease.

The Phase 1b registrational study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of SER-252 in patients with advanced Parkinson’s disease whose symptoms are inadequately controlled by current standard-of-care therapies. Serina anticipates that blinded review of safety and tolerability by the Safety Monitoring Committee from Cohort 1 will allow advancement to Cohort 2 in the third quarter of 2026.

“Dosing the first patient represents an important inflection point for Serina as we begin generating clinical data with SER-252,” said Steve Ledger, Chief Executive Officer of Serina. “With FDA alignment on our 505(b)(2) NDA pathway and recognition of this Phase 1b trial as registrational, we are positioned to efficiently generate the clinical data necessary to bring SER-252 to market. We are grateful to our clinical investigators, the Parkinson’s community in Australia, and the patients who are making this trial possible.”

Serina has established relationships with Parkinson’s Australia and Neuroscience Trials Australia to support patient identification and enrollment activities. The Company plans to provide further updates on the trial as patient enrollment progresses.

Initial dosing activities are underway at global clinical sites, including Australia, where Serina has established strong investigator relationships to support efficient trial execution. The Company expects to provide additional clinical and operational updates as the study advances.

About Serina Therapeutics

Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ Platform^™ provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology.

About the POZ Platform^™

Serina’s proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Serina’s POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. The therapeutic agents in Serina’s product candidates are typically well-understood and marketed drugs that are effective but are limited by pharmacokinetic profiles that can include toxicity, side effects and short half-life. Serina believes that by using POZ technology, drugs with narrow therapeutic windows can be designed to maintain more desirable and stable levels in the blood.

Serina’s POZ platform delivery technology has potential for use across a broad range of payloads and indications. Serina intends to advance additional applications of the POZ platform via out-licensing, co-development, or other partnership arrangements, including the non-exclusive license agreement with Pfizer, Inc. to use Serina’s POZ polymer technology for use in lipid nanoparticle drug (LNP) delivery formulations.

About SER-252 (POZ-apomorphine)

SER-252 is an investigational apomorphine therapy developed with Serina’s POZ platform and designed to provide continuous dopaminergic stimulation (CDS). CDS has been shown to reduce the severity of levodopa-related motor complications (dyskinesia) in Parkinson’s disease. Preclinical studies support the potential of SER-252 to provide CDS without skin reactions.

Cautionary Statement Regarding Forward-Looking Statements

This release contains forward-looking statements within the meaning of federal securities laws. All statements that are not historical fact, including statements about Serina’s planned clinical programs, including timing for patient enrollment and dosing, the potential of Serina’s POZ polymer technology, and the Company’s ability to advance its clinical trial, are forward-looking statements that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements are based on management’s current expectations, plans, beliefs or forecasts for the future, and are subject to uncertainty and changes in circumstances. Undue reliance should not be placed on these forward-looking statements which speak only as of the date they are made, and the facts and assumptions underlying these statements may change.

Actual results may differ materially from those projected in such statements due to a variety of important factors including, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; Serina’s ability to continue as a going concern; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any applications may be filed for any drug or vaccine candidates in any jurisdictions; whether and when regulatory authorities may approve any potential applications that may be filed for any drug or vaccine candidates in any jurisdictions, which will depend on a myriad of factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether any such drug or vaccine candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of any drug or vaccine candidates; and competitive developments. These risks as well as other risks are more fully discussed in the company’s Annual Report on Form 10-K for the year ended December 31, 2024, and the company’s other periodic reports and documents filed from time to time with the SEC. The information contained in this release is as of the date hereof, and Serina assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

For inquiries, please contact:
Stefan Riley
sriley@serinatherapeutics.com
(256) 327-9630